Compare · CNC vs NTRA
CNC vs NTRA
Side-by-side comparison of Centene Corporation (CNC) and Natera Inc. (NTRA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CNC and NTRA operate in Medical Specialities (Health Care), so they compete in similar markets.
- NTRA is the larger of the two at $46.24B, about 1.4x CNC ($32.22B).
- Over the past year, CNC is up 120.3% and NTRA is up 89.5% - CNC leads by 30.8 points.
- CNC has been more active in the news (13 items in the past 4 weeks vs 6 for NTRA).
- Both have 25 recent analyst ratings on file.
- Company
- Centene Corporation
- Natera Inc.
- Price
- $65.22+1.35%
- $320.90-0.30%
- Market cap
- $32.22B
- $46.24B
- 1M return
- +2.27%
- +18.71%
- 1Y return
- +120.26%
- +89.47%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2015
- News (4w)
- 13
- 6
- Recent ratings
- 25
- 25
Centene Corporation
Centene Corporation operates as a multi-national healthcare enterprise that provides programs and services to under-insured and uninsured individuals in the United States. Its Managed Care segment offers health plan coverage to individuals through government subsidized programs, including Medicaid, the State children's health insurance program, long-term services and support, foster care, and medicare-medicaid plans, which cover dually eligible individuals, as well as aged, blind, or disabled programs. Its health plans include primary and specialty physician care, inpatient and outpatient hospital care, emergency and urgent care, prenatal care, laboratory and X-ray, home-based primary care, transportation assistance, vision care, dental care, telehealth, immunization, specialty pharmacy, therapy, social work, nurse advisory, and care coordination services, as well as prescriptions and limited over-the-counter drugs, medical equipment, and behavioral health and abuse services. This segment also offers various individual, small group, and large group commercial healthcare products to employers and directly to members in the Managed Care segment. The company's Specialty Services segment provides pharmacy benefits management services; nurse advice line and after-hours support services; and vision and dental services, as well as staffing services to correctional systems and other government agencies; and services to Military Health System eligible beneficiaries. This segment offers its services and products to state programs, correctional facilities, healthcare organizations, employer groups, and other commercial organizations. The company provides its services through primary and specialty care physicians, hospitals, and ancillary providers. Centene Corporation was founded in 1984 and is headquartered in St. Louis, Missouri.
Natera Inc.
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.
Latest CNC
- Centene Appoints New Chief Information Officer
- Secretary & General Counsel Koster Christopher sold $3,779,850 worth of shares (56,500 units at $66.90), decreasing direct ownership by 19% to 248,854 units (SEC Form 4)
- California Community Health Workers and Doulas Can Spend More Time Helping Medi-Cal Members, Thanks to Health Net's $900,000 Grant to Pear Suite
- Coordinated Care Brings Free Health Screenings to Washington Communities with Statewide Vision & Dental Van Tour
- Superior HealthPlan has supported more than 312,000 Texas pregnancies since 2022 through the Start Smart for Your Baby® program
- Secretary & General Counsel Koster Christopher sold $3,111,332 worth of shares (47,603 units at $65.36), decreasing direct ownership by 13% to 305,354 units (SEC Form 4)
- Centene Corporation filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Centene Announces Planned Chief Financial Officer Transition
- Sixty Compton, California Students to be Selected for Leadership and Health Advocacy Training, Powered by Health Net's $412,000 Investment
- Carolina Complete Health Supports Young Leaders Through AMEXCAN Summer Camp
Latest NTRA
- New Publication Establishes Strong Clinical Validation of Signatera™ for MRD Assessment in Lymphoma
- PRESIDENT, CHIEF BUS. OFFICER Fesko John was granted 20,000 shares and sold $2,095,411 worth of shares (6,517 units at $321.53) as part of a pre-agreed trading plan, increasing direct ownership by 7% to 197,257 units (SEC Form 4) (tax liability)
- Natera and Susan G. Komen® Announce National Partnership to Accelerate Progress Against Breast Cancer
- Natera and Angiex Partner to Assess Response to Investigational Nuclear-Delivered Antibody-Drug Conjugate™ Using Signatera™
- CO-FOUNDER Sheena Jonathan sold $1,951,942 worth of shares (6,000 units at $325.32) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 230,464 units (SEC Form 4)
- Natera to Support New Clinical Trial Assessing ctDNA Dynamics with Latitude™ in Advanced Skin Cancers
- CO-FOUNDER Sheena Jonathan sold $2,888,325 worth of shares (9,150 units at $315.66) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 236,464 units (SEC Form 4)
- EXECUTIVE CHAIRMAN Rabinowitz Matthew sold $641,800 worth of shares (2,000 units at $320.90) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form S-8 filed by Natera Inc.
- SEC Form 10-Q filed by Natera Inc.